Wuxi

WuXi to go private as part of $3.3bn deal

WuXi to go private as part of $3.3bn deal

By Zachary Brennan

A group of investors, shareholders and executives of China-based CDMO WuXi are taking the company private in a deal worth about $3.3bn.

Tigermed Envy? WuXi may be eyeing a launch on Shenzhen exchange

Tigermed Envy? WuXi may be eyeing a launch on Shenzhen exchange

By Zachary Brennan

With WuXi pushing full steam ahead in its bid to go private, one expert says that the company may be envious of a competing CRO -- Hangzhou Tigermed, which is smaller than WuXi but valued at a higher price on the Shenzhen stock exchange.

WuXi offers more details on the complexity of CRO, CMO competition

WuXi offers more details on the complexity of CRO, CMO competition

By Zachary Brennan

Competition in the notoriously tight-lipped CRO (contract research organization) and CMO (contract manufacturing organization) industries is getting fiercer as outsourcing picks up, though that hasn’t stopped one Chinese company from revealing who it...

WuXi sells small share of CMO subsidiary for $28m

WuXi sells small share of CMO subsidiary for $28m

By Zachary Brennan

Chinese service provider WuXi PharmaTech has sold a 5.55% stake in its wholly owned CMO (contract manufacturing organization) subsidiary SynTheAll Pharmaceutical (STA) to members of STA’s and WuXi’s management for $28m.

CFDA accepts WuXi-MedImmune’s IND for new mAb

CFDA accepts WuXi-MedImmune’s IND for new mAb

By Zachary Brennan

The China Food and Drug Administration (CFDA) has accepted for review an Investigational New Drug (IND) application for WuXi and MedImmune's novel anti-IL6 monoclonal antibody (mAb) for rheumatoid arthritis. 

Small molecule manufacturing currently represents more than 27% of total company revenue

Small molecule, biologics manufacturing drive WuXi growth in Q2

By Zachary Brennan

With almost 20% year-over-year growth in its manufacturing services, Chinese CRO and CMO WuXi now expects its small molecule manufacturing and biologics to be the key drivers of growth for the next several years, Ge Li, chairman and CEO of WuXi, said.

PRA and Wuxi team in China

Wuxi and PRA team in China

By Gareth Macdonald

Local knowledge and global experience should be enough to see PRA and Wuxi PharmaTech buck the trend of failed China JVs, says analyst.

Wuxi repurchases shares

Wuxi repurchases shares

China-based CRO Wuxi PharmaTech has repurchased shares from private equity fund General Atlantic LLC.

WuXi grows in Q3

WuXi grows in Q3

By Nick Taylor

WuXi PharmaTech’s operating income increased by 35 per cent in the third quarter, underpinned by strong growth in China-based laboratory services, but its manufacturing operations continue to struggle.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers